
Rubraca 300mg Tablet - 60 Tablets, Oral Dosage | Parp Inhibitor For Advanced Ovarian Cancer, Targeted Therapy With Improved Survival
Get Latest Price
In Stock
Product Specifications
| Dosage | 300mg |
| Features | Cancer treatment, PARP inhibitor, Ovarian cancer, Targeted therapy, Improved survival |
| Form | Tablet |
| Packaging | Bottle |
| Quantity | 60 tablets |
| Route | Oral |
Product Overview
Key Features
Rubraca is specifically indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Patients should be selected for therapy based on an FDA-approved companion diagnostic for Rubraca.
Company Details
Business Type
Exporter, Distributor
Employee Count
100
Establishment
1987
Working Days
To
Payment Mode
Western Union
Related Products
Explore Related Categories
More Products From This Seller
Seller Details
Palghar, Maharashtra
Accepts only Foreign inquiries
Name
Jiten Aggarwal
Address
Address: H.301 Maxheal house, tarapur industrial area, Dist. Palghar, Maharashtra, 401506, India
life saving drug in Palghar
Report incorrect details



































